8-K filing — Yarrow Bioscience, Inc. (YARW)
Filed: 2026-09-14 AccNo: 0001104659-26-107485 Size: 582 KB Item 1.01: Entry into a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Yarrow Bioscience Launches Underwritten Public Offering To Fund Pipeline Development And Corporate Operations; No Terms Disclosed
Yarrow Bioscience, Inc. ("Yarrow" or the "Company") (NASDAQ:YARW), a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases, today announced
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Reported Earlier, Yarrow Bioscience Prices $150M Underwritten Public Offering Of 5,769,231 Shares At $26.00 Per Share
Yarrow Bioscience Q2 EPS $(2.14) Misses $(0.22) Estimate
Yarrow Bioscience (NASDAQ:YARW) reported quarterly losses of $(2.14) per share which missed the analyst consensus estimate of $(0.22) by 872.73 percent.